ZTS · Q2 2026 Earnings

Bearish

Zoetis

Reported August 6, 2026

30-second summary

30-second take: Zoetis missed Q2 revenue at $2.468B (-1.7% vs $2.51B consensus, flat YoY) while beating EPS at $1.87 ($0.02 above), then cut FY2026 guidance for the second consecutive quarter — revenue midpoint down ~$600M to $9.12–$9.32B, adjusted EPS midpoint down 10.4% to $6.15–$6.25, and organic operational growth flipped from +2% to +5% to -3% to -1%. U.S. Companion Animal collapsed another 11% YoY to $1.044B, matching Q1's decline and confirming the deterioration is structural, not transitional. This is a thesis break: management is now guiding to negative organic growth for the year, has withdrawn reported EPS guidance entirely, and is reaching for "adapting our commercial strategy to the marketplace in front of us" — the verbal admission that the FY2026 plan set five months ago no longer applies.

Headline numbers

EPS

Q2 FY2026

$1.87

+1.1% vs est.

Revenue

Q2 FY2026

$2.47B

+0.0% YoY

-1.7% vs est.

Gross margin

Q2 FY2026

72.8%

Key financials

Q2 FY2026

Metric	Q2 FY2026	Q2 FY2025	YoY	Q1 FY2026	QoQ
Revenue	$2.47B	$2.46B	+0.3%	$2.26B	+9.1%
EPS	$1.87	$1.76	+6.3%	$1.53	+22.2%
Gross margin	72.8%	73.6%	-80bps	71.7%	+110bps

Guidance

Significant full-year guidance cut across all major metrics: FY2026 EPS lowered ~10%, revenue reduced ~6%, and organic growth swung from positive to negative, signaling material business headwinds particularly in companion animal segment.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY 2026	$9.68B to $9.96B	$9.12B to $9.32B	-$0.56B to -$0.64B (midpoint -$0.60B)	Lowered
Adjusted Diluted EPS	FY 2026	$6.85 to $7.00	$6.15 to $6.25	-$0.70 to -$0.75 (midpoint -$0.725)	Lowered
Adjusted Net Income	FY 2026	$2.87B to $2.95B	$2.57B to $2.62B	-$0.30B to -$0.33B (midpoint -$0.315B)	Lowered
Reported Diluted EPS	FY 2026	$6.35 to $6.50	Withdrawn — no replacement	—	Withdrawn

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
U.S. Companion Animal	$1.044B	—	-11.0%
U.S. Livestock	$0.222B	—	+23.0%
International Companion Animal	$0.664B	—	+5.0%
International Livestock	$0.509B	—	+6.0%
Dogs and Cats	$1.634B	$1.716B	-4.8%
Cattle	$0.39B	$0.32B	+21.9%
Poultry	$0.115B	—	+10.0%
Companion Animal Organic Revenue Growth	-6%	—	—
Livestock Organic Revenue Growth	10%	—	—

Other KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
U.S. Segment Gross Margin	83.1%	—	—
International Segment Gross Margin	71.0%	—	—
U.S. Organic Revenue Decline	-7%	—	—
International Organic Revenue Growth	6%	—	—
Pipeline Blockbuster Candidates	>12 potential blockbusters	—	—
FY2026 Adjusted EPS Guidance (revised)	$6.15–$6.25	—	—

Management tone

Q3 FY2025 → Q4 FY2025 → Q1 FY2026 → Q2 FY2026: Broadening therapeutic-visit declines → Algorithm reset to 3–5% → Decisive action + guide cut → Adapting to the marketplace in front of us.

Three quarters ago management was defending an insulation-from-vet-softness narrative. Two quarters ago they reset the algorithm to 3–5% organic growth. Last quarter they cut to 2–5% while promising "decisive action." This quarter they cut again — to negative organic growth — and the language has moved from action to acceptance: "We are adapting our commercial strategy to the marketplace in front of us, deploying targeted investments, accelerating innovation, and pursuing business development to strengthen our position." "The marketplace in front of us" is the verbal concession that the FY2026 plan set at the February guide was built for a different environment than the one Zoetis is operating in. When management stops talking about returning to the algorithm and starts talking about adapting to reality, the algorithm has been abandoned.

The introduction of "pursuing business development" is a meaningful escalation from prior quarters. Zoetis has been an organic growth story with bolt-on M&A characterized as opportunistic. Explicitly naming BD as a strategic lever in the same paragraph as a 10% EPS cut signals management is looking at inorganic solutions to fill an organic hole — either portfolio pruning, licensing deals, or acquisition. This is the language of a company preparing investors for a portfolio reshape.

The Livestock-as-diversification framing has hardened from footnote to headline. The Q1 language emphasized companion animal recovery paths; this quarter's qualitative statements lead with "we continue to benefit from the breadth of our diversified portfolio, including strength in Livestock and Diagnostics." When a companion-animal-first company starts leading its narrative with Livestock, the internal center of gravity has shifted — and that shift acknowledges companion animal weakness is not near-term reversible.

The pipeline language is unchanged — "a significant approval in a major market every year for the next several years" and "12+ potential blockbuster candidates" appear verbatim from prior quarters. The stability of the pipeline framing amid deteriorating operating guidance is itself a signal: the pipeline is the only piece of the bull thesis management still feels comfortable defending, which puts enormous weight on Lenivia and Portela executing in H2 FY2026 and 2027.

Answers to last quarter's watch list

Q2 FY2026 U.S. Companion Animal print — U.S. Companion Animal came in at $1.044B, -11% YoY, matching Q1's -11% decline. Two consecutive double-digit contractions in the largest segment confirm this is a structural running rate, not a one-quarter fiscal-alignment artifact. The prior watch item explicitly flagged this outcome as "invalidating the 2–5% FY range and forcing a second cut" — that is exactly what happened. Status: Resolved negatively

H2 FY2026 organic operational growth implied by Q2 print — With Q2 also flat/negative on organic operational (Companion Animal organic -6%, Livestock organic +10% blending to well below the prior guide range), the FY 2–5% range was mechanically unreachable — and management cut it to -3% to -1% rather than defending it. The H2 inflection thesis is gone. Status: Resolved negatively

Adjusted vs reported EPS divergence — Management resolved this by withdrawing reported EPS guidance entirely rather than quantifying the underlying non-GAAP charges. That is a worse outcome than either scenario contemplated in Q1: the gap between adjusted and reported is now so wide, or so uncertain, that management has removed the disclosure. Adjusted EPS midpoint came down another 10.4% ($0.725) this quarter. Status: Resolved negatively

Pricing realization vs the new 1–2% assumption — The press release does not quantify Q2 pricing contribution; without transcript commentary, the pricing realization read is unresolved. However, the fact that organic operational revenue growth was cut another 500bps at the midpoint strongly implies pricing came in at or below the 1% floor. Status: Continue monitoring

Distributor inventory and the 200–250bps fiscal alignment tailwind — No press-release disclosure on distributor inventory or an underlying FY2027 algorithm ex the alignment benefit. Management did not use this quarter to frame the FY2027 starting point despite the FY2026 collapse. Status: Continue monitoring

Librela U.S. patient starts ahead of Lenivia/Portela launches — No hard U.S. patient starts figure disclosed. The Companion Animal organic decline of -6% (worse than Q1's -4%) strongly suggests OA pain franchise pressure has not stabilized. Status: Continue monitoring

What to watch into next quarter

Q3 FY2026 U.S. Companion Animal print vs the -11% Q1/Q2 running rate — a third consecutive -11% read would mechanically drive the FY organic range toward the -3% floor and raise the risk of a fourth cut. Any stabilization above -8% would validate the low end of the new -3% to -1% guide.

Q3 FY2026 organic operational revenue growth — using the prior-year baseline of $2.40B, the new -3% to -1% FY guide combined with Q1/Q2 actuals implies H2 organic operational needs to average roughly -3% to hit the midpoint. Any Q3 print below -4% organic operational puts the current guide floor at risk within one quarter.

Business development actions — management's explicit invocation of "pursuing business development" signals inorganic activity is on the table. Watch for announced portfolio pruning, licensing deals, or an acquisition in the next 1-2 quarters; the framing has shifted enough that BD is no longer opportunistic.

Reported EPS re-disclosure — the withdrawal of reported EPS guidance is a rare and material transparency step-down. Watch whether Q3 reintroduces a reported EPS range (indicating charge visibility has improved) or continues to disclose adjusted only (indicating restructuring is ongoing and larger than currently sized).

Lenivia and Portela U.S. launch trajectory — with the pipeline the only remaining piece of the bull narrative management is defending, execution on the first material launches becomes existential. Watch for any hard datapoints on Canada/EU uptake and U.S. approval timing.

Adjusted gross margin path — Q2's 72.8% (+100bps QoQ) is the one operating line moving in the right direction. Watch whether Q3 sustains sequential expansion or whether volume deleverage from Companion Animal contraction reverses the trend.

Sources

Zoetis Q2 FY2026 earnings press release (SEC EDGAR filing, exhibit99q22026.htm)
Prior Zoetis quarterly briefs (Q2 FY2025 through Q1 FY2026) for cross-quarter guidance and tone comparison

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.